Work

Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps9119

Authors: Rachel Lubong Sabado, Anna C. Pavlick, Sacha Gnjatic, Patrick Alexander Ott, Farah Hasan, Meredith Spadaccia, Isabelita Vengco, Rose Marie Holman, Caroline Muren, Crystal Escano, Ethel Yepes, Claire Stein, Achim A Jungbluth, Linda S. Pan, Ralph Rudolph Venhaus, Nina Bhardwaj

Institutions: Icahn School of Medicine at Mount Sinai, NYU Langone Health, Dana-Farber Cancer Institute, New York University, Ludwig Cancer Research, Tisch Cancer Institute

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603602989

Cites:

Cited by: 3

Related to: 10